Drug Profile
Research programme: antibody drug conjugates - Sutro Biopharma
Alternative Names: DBCO-Alexa647-conjugated SP7219; SP 7676Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Sutro Biopharma
- Class Antineoplastics; Bispecific antibodies; Immunoconjugates
- Mechanism of Action Invariant chain inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
- 19 Sep 2016 Preclinical trials in Cancer in USA (Parenteral) before September 2016
- 09 Sep 2014 Sutro Biopharma and University of California, San Francisco collaborate on the generation of synthetic antibodies